Hatchtech Pty Ltd. is the developer of a proprietary next generation head lice treatment, DeOvo™, which has successfully completed two pivotal Phase III clinical studies. The company plans to file a New Drug Application with the Food and Drug Administration (FDA) in the United States in the first half of 2015.

DeOvo™, recently renamed as Xeglyze™ Lotion, is a head lice product in development that has been shown through clinical studies to kill both lice and eggs; treating all life cycle stages of the organism in a single application.

Xeglyze™ is a cosmetically elegant topical lotion containing an inhibitor of metal dependent targets that are involved in all stages of the louse lifecycle from egg to adult. A substantial body of scientific data has established the mode of action and preclinical and clinical studies have shown Xeglyze ™ to be both highly effective and safe.

While other head lice treatments treat the lice, few are effective against the eggs, hence requiring repeat applications to eliminate an infestation. In addition, while head lice worldwide have developed resistance to many of the available products, the novel mode of action in Hatchtech’s product Xeglyze™, when compared to other current active ingredients, means that there is no known cross resistance with Xeglyze™.

Hatchtech is securely financed by a consortium of specialist venture capitalists and is located in Melbourne, Australia.

Latest News

Oct 21, 2014 Hatchtech Announces Successful Results from Phase 2 Ovicidal Study

Sep 02, 2014 Hatchtech Announces Successful Phase 3 Results

Dec 11, 2013 Hatchtech Receives SPA and Announces Patent Grants

Oct 31, 2013 Hatchtech Completes $12.6m Capital Raise, Secures Funds for Phase III and NDA Submission